Clinical Trial Update: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the combination of ametinib and bevacizumab as first-line treatment for advanced non-small cell lung cancer with EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ametinib (ametinib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: The Second Affiliated Hospital of Shandong First Medical University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN